Spirocyclic amides as cannabinoid receptor modulators
CA 2479618 A1 · Owner: Hagmann, William K. · Inventors: Goulet, Mark T.; Shah, Shrenik K.; Lin, Linus S.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits cognitive disorders, migraine, neuropathy neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis cerebral vascular accidents, and head trauma anxiety disorders, stress, epilepsy, Parkinson s disease movement disorders, and schizophrenia. The compounds are also useful for …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 21, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 21, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 21, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.